<DOC>
	<DOCNO>NCT00736242</DOCNO>
	<brief_summary>The objective study assess safety efficacy peginterferon alfa-2b ( PEG-IFN alfa-2b ) ribavirin ( RBV ) administer participant coinfected Human Immunodeficiency Virus ( HIV ) Hepatitis C Virus ( HCV ) . Participants treat general practitioner clinical practice part post-marketing surveillance study . The study assess rate eradication HCV rate serious adverse event report PEG-IFN alfa-2b ( 1.5 ug/kg/week ) RBV ( 800-1200 mg/day ) common medical practice Germany .</brief_summary>
	<brief_title>Post-marketing Surveillance HIV-infected Patients With Chronic Hepatitis C Treated With PegIntron Pen Rebetol ( Study P04584 )</brief_title>
	<detailed_description>In observational , non-interventional study , time enrollment start treatment sole decision physician . No investigational medicinal product provide sponsor .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Peginterferon alfa-2b</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<criteria>≥ 18 year age eligible treatment accord Summary Product Characteristics ( SmPC ) Presence chronic Hepatitis C ( elevate liver enzymes without decompensation ) Presence HCVRNA know genotype infect hepatitis C virus HIV infection confirm positive Enzyme Linked Immunosorbent Assay ( ELISA ) Western blot Cluster differentiation ( CD ) 4 cell count &gt; 200/mL Treatmentnaïve Platelets ≥ 75,000/mm^3 Neutrophil count ≥ 1,500/mm^3 Thyroid Stimulating Hormone ( TSH ) must within normal limit Hemoglobin ≥ 10 g/dL ( female ) ; ≥ 11 g/dL ( male ) Women childbearing potential must routine pregnancy test perform monthly treatment 7 month thereafter . Sexually active female participant childbearing potential must practice adequate contraception ( intrauterine device , oral contraceptive , implanted contraceptive , surgical sterilization , barrier method , monogamous relationship male partner vasectomy use condom ( + spermicide ) treatment period 7 month stop treatment . Sexually active male participant must practice acceptable method contraception ( vasectomy , use condom + spermicide , monogamous relationship female partner practice acceptable method contraception ) treatment period 7 month stop treatment . Contraindications accord European approval SmPC Pretreatment chronic hepatitis C Liver decompensation Hypersensitivity active substance interferon excipients Pregnant woman Women breast feeding Existence history psychiatric condition , particular depression , suicidal ideation suicide attempt A history severe preexist cardiac disease , include unstable uncontrolled cardiac disease previous six month Severe debilitate medical condition , include participant chronic renal failure creatinine clearance &lt; 50 ml/min . Autoimmune hepatitis history autoimmune disease Severe hepatic dysfunction decompensated cirrhosis liver Preexisting thyroid disease unless control conventional therapy Epilepsy and/or compromise central nervous system function</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>HIV</keyword>
</DOC>